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Sexamined at 1 (n¼19 devices), 3 (n¼21), 6 (n¼21), 12 (n¼21), 18 (n¼19), 24
(n¼19), 30 (n¼20), 36 (n¼20), and 42 mo. (n¼21) by light microscopy or scanning
electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and
gel permeation chromatography (GPC) analysis were performed at various time
points.
Results: Vascular responses to BVS and XV were largely comparable at all time
points, with struts being sequestered in neointima. SEM conﬁrmed rapid endothelial
coverage by 1 mo. in both BVS and XV implanted arteries. Inﬂammation was
minimal to mild for both devices, though from 12 to 36 mo. mean scores were
greater for BVS. Pharmacokinetics revealed a similar drug release proﬁles for BVS
and XV. Consistent with drug elution, ﬁbrin deposition was similar between BVS
and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histo-
morphometry showed positive remodeling in BVS-implanted arteries that started
beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were
observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS
were poorly discernible from the surrounding neointima. GPC analysis conﬁrmed
that degradation of BVS could be considered complete by 36 mo. Additional
histochemical staining demonstrated inﬁltration of proteoglycans and collagen
between acellular homogenous hyaline material in resorption sites of BVS beginning
beyond 12 mo. with resorption sites being near completely composed of connective
tissue by 42 mo.
Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries
with positive remodeling,minimal inﬂammation, and near complete degradation at 36mo.TCT-811
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Background: Intracoronary infusion of stem cells has typically been administered
through a standard single lumen, over-the-wire (OTW) 0.014" balloon catheter. These
catheters are not optimized for stem cell delivery, can compromise stem cell viability
and potential clinical efﬁcacy.
Methods: A Mesenchymal Stem Cell (MSC) solution with cell concentration of
2.5x106/ml was infused through a standard single lumen over-the-wire (OTW) 0.14"
balloon catheter during balloon inﬂation at 6, 8, 10 and 12 atmospheres (atms) at
a ﬂow rate of 1ml/min and during balloon inﬂation at 8 and 12 atms at ﬂow rate of
4ml/min. MSC samples were tested using trypan blue for viability before and after
passing through the standard balloon catheter wire lumen.
Results: Physical measurement of the inner lumen demonstrated collapsing of the
wire lumen during balloon inﬂation. Infusing through the catheter at a ﬂow rate of
1ml/minute, cell viability decreased from (97.5% to 91.7%), (95.7% to 94.1%),
(94.9% to 86.0%), (97.9% to 76.7%) at 6, 8, 10, and 12 atms respectively. When ﬂow
was increased to 4ml/minute, the cell survival decreased from (92.3% to 62.0%) and
from (91.3% to 60.8%) at 8 and 12 atms respectively.
Conclusions: A standard single lumen, over-the-wire (OTW) 0.014" angioplasty
balloon catheter can decrease stem cell viability and potentially affect the clinical
outcome of stem cell therapy.TCT-812
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Background: There is little available data regarding the long term follow-up of
patients treated with drug-eluting stent (DES) for Unprotected Left Main (ULM)
according to chronic kidney disease determined by estimated GFR (e-GFR).
Methods: All 1032 consecutive patients treated with DES implantation (ﬁrst and
second generation) for ULM stenosis between April 2005 and August 2011 were
retrospectively assessed for impact of renal function. Patients were classiﬁed into
normal renal function (60<; 567 patients), mild (30<60; 367 patients), moderateB246 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j(15<30; 41 patients) and severe (<15; 57 patients) renal function groups. The
end-point of the study was a composite of major adverse cardiovascular events
(MACE) deﬁned as all cause death, myocardial infarction (MI) and TLR. Further-
more, the individual components of MACE, cardiac death, deﬁnite/probable stent
thrombosis (ST), possible ST and TLR for main-branch (TLR-MB) were evaluated.
Results: Patients with a lower e-GFR had more co-morbidities and complex lesions.
MACE, all cause death, cardiac death, TLR-MB, MI and deﬁnite/probable ST and
possible ST were more frequently observed when patients had more compromised
renal function (MACE at 5-years 33.1% in overall; 25.9% in normal, 35.0% in mild,
50.7% in moderate and 82.3% in severe, all cause death 17.0%; 10.1%, 18.0%,
42.8% and 68.1%,cardiac death 7.3%; 3.3%. 8.3%, 23.2% and 46.2%, TLR-MB
9.5%; 7.2%, 9.7%, 10.8% and 34.8% and MI 3.4%; 1.3%, 3.7%, 12.6% and 26.1%,
deﬁnite/probable ST 1.9%; 0.8%, 1.7%, 7.6% and 10.7%, and possible ST 5.2%;
1.9%, 5.7%, 14.6% and 38.5%, respectively). An estimated GFR was strongly
associated with all death (adjusted HR 0.979; 95%CI 0.972-0.987, p<0.001),
cardiac-death (adjusted HR 0.966; 95%CI 0.941-0.979, p<0.001), deﬁnite/probable
ST (HR 0.973; 95%CI 0.951-0.996, p¼0.024), possible ST (adjusted HR 0.964;
0.950-0.978, p<0.001) and TLR-MB (adjusted HR 0.987; 95%CI 0.977-0.997,
p¼0.009).
Conclusions: PCI in patients with ULM disease, the severity of CKD as determined
by estimated GFR, was associated with an increased risk of clinical events. Some of
adverse events may be related to progression of CKD.TCT-813
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Background: Although many biodegradable polymer based technologies are widely
used and tested in the clinical settings, still there is lack of data showing degradation
kinetics of a polymer in-vivo. The aim of this preclinical analysis was an evaluation of
sirolimus kinetics and biodegradable polymer (BP, poly-lactic acid) absorption from
the surface of drug eluting stent using a novel nuclear magnetic resonance (NMR)
method.
Methods: In 18 domestic swine 18 BP only coated stents (BPS) and 36 biodegradable
polymer sirolimus eluting stents (BP-SES) where implanted with 110% overstretch.
The animals were sacriﬁced at 1, 3, 7, 14, 28 and 56 days follow-up (9 segments per
time point). Vessel segments with BPS were harvested to evaluate polymer degra-
dation with a novel NMR method, whereas BP-SES to test sirolimus tissue uptake and
retention. In the NMR method a cryoplatform and cryoprobe were used to optimize
observation of resonance signals in H-1 NMR spectrum. The lactide molecules as an
internal standard were used to conﬁrm quantity of polymers on stent surface. Siroli-
mus pharmacokinetic analysis was performed with the use of standard liquid chro-
matography (HPLC) method in order to check its correlation with BP absorption as the
polymer degradation and drug release should run almost in parallel during the ﬁrst
four weeks after stent implantation.
Results: The NMR method showed a gradual absorption of the polymer over the
six consecutive time points, from 5.48 mg of the polymer on the stent at 1 day
follow-up, through 4.33 mg at 3 days, 3.16 mg at 7 days, 2.42 mg at 14 days, 1.92
mg at 28 days to 1.24 mg in the last day of the study. In addition this method
showed a good correlation with widely used and standardized HPLC method for
sirolimus elution.
Conclusions: The novel NMR method for BP absorption kinetics evaluation is
a useful tool which may be widely adopted to test other biodegradable applications.
Further, it may substantially improve their safety and efﬁcacy by facilitating pro-
grammed polymer and drugs elution. The polymer degradation pattern will be
essential in designing a study with the aim to shorten double antiplatelet therapy.TCT-814
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Background: X-Ray with its known disadvantages of iodinated contrast agents,
ionizing radiation and lack of soft tissue contrast is currently used for percutaneous
closure of PFOs, ASDs and VSDs. Cardiac MRI imaging is compromised by the
artifacts of commercial occluders that have been tested. The new MR-Enhancing
occluder functions as a local ampliﬁer of the MRI signal and improves imaging and
MRI guided closure.
Methods: Resonant occluder manufactured from a Nitinol tube (Ø ¼ 0.2 mm) is
designed so that it includes inductivity and capacity necessary for a resonant circuit.TCT Abstracts/POSTER/Basic Science, Animal Models, and Cell Therapy
